

Non-oncology Biopharmaceuticals Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/N0FB8405C4DCEN.html>

Date: February 2022

Pages: 118

Price: US\$ 3,250.00 (Single User License)

ID: N0FB8405C4DCEN

Abstracts

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.

This report contains market size and forecasts of Non-oncology Biopharmaceuticals in Global, including the following market information:

Global Non-oncology Biopharmaceuticals Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Non-oncology Biopharmaceuticals market was valued at 304180 million in 2021 and is projected to reach US\$ 519380 million by 2028, at a CAGR of 7.9% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Biologics Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva and Eli Lilly, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-oncology Biopharmaceuticals companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non-oncology Biopharmaceuticals Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Non-oncology Biopharmaceuticals Market Segment Percentages, by Type, 2021 (%)

Biologics

Biosimilars

Global Non-oncology Biopharmaceuticals Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Non-oncology Biopharmaceuticals Market Segment Percentages, by Application, 2021 (%)

Immunology

Endocrinology

Others

Global Non-oncology Biopharmaceuticals Market, By Region and Country, 2017-2022,
2023-2028 (\$ Millions)

Global Non-oncology Biopharmaceuticals Market Segment Percentages, By Region and
Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non-oncology Biopharmaceuticals revenues in global market,
2017-2022 (estimated), (\$ millions)

Key companies Non-oncology Biopharmaceuticals revenues share in global market,
2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Sanofi

Johnson & Johnson

Pfizer

Novo Nordisk

Novartis

Merck

Teva

Eli Lilly

Bristol-Myers Squibb

GlaxoSmithKline

UCB Pharma

Amgen

AbbVie

Takeda

AstraZeneca

Mylan

LEO Pharma

Boehringer Ingelheim

Alexion Pharmaceuticals

Elusys Therapeutics

Swedish Orphan Biovitrum

Biogen

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Non-oncology Biopharmaceuticals Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Non-oncology Biopharmaceuticals Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NON-ONCOLOGY BIOPHARMACEUTICALS OVERALL MARKET SIZE

- 2.1 Global Non-oncology Biopharmaceuticals Market Size: 2021 VS 2028
- 2.2 Global Non-oncology Biopharmaceuticals Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Non-oncology Biopharmaceuticals Players in Global Market
- 3.2 Top Global Non-oncology Biopharmaceuticals Companies Ranked by Revenue
- 3.3 Global Non-oncology Biopharmaceuticals Revenue by Companies
- 3.4 Top 3 and Top 5 Non-oncology Biopharmaceuticals Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Non-oncology Biopharmaceuticals Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Non-oncology Biopharmaceuticals Players in Global Market
 - 3.6.1 List of Global Tier 1 Non-oncology Biopharmaceuticals Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Non-oncology Biopharmaceuticals Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Non-oncology Biopharmaceuticals Market Size Markets, 2021 & 2028

4.1.2 Biologics

4.1.3 Biosimilars

4.2 By Type - Global Non-oncology Biopharmaceuticals Revenue & Forecasts

4.2.1 By Type - Global Non-oncology Biopharmaceuticals Revenue, 2017-2022

4.2.2 By Type - Global Non-oncology Biopharmaceuticals Revenue, 2023-2028

4.2.3 By Type - Global Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Non-oncology Biopharmaceuticals Market Size, 2021 & 2028

5.1.2 Immunology

5.1.3 Endocrinology

5.1.4 Others

5.2 By Application - Global Non-oncology Biopharmaceuticals Revenue & Forecasts

5.2.1 By Application - Global Non-oncology Biopharmaceuticals Revenue, 2017-2022

5.2.2 By Application - Global Non-oncology Biopharmaceuticals Revenue, 2023-2028

5.2.3 By Application - Global Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Non-oncology Biopharmaceuticals Market Size, 2021 & 2028

6.2 By Region - Global Non-oncology Biopharmaceuticals Revenue & Forecasts

6.2.1 By Region - Global Non-oncology Biopharmaceuticals Revenue, 2017-2022

6.2.2 By Region - Global Non-oncology Biopharmaceuticals Revenue, 2023-2028

6.2.3 By Region - Global Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Non-oncology Biopharmaceuticals Revenue, 2017-2028

6.3.2 US Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.3.3 Canada Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.3.4 Mexico Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Non-oncology Biopharmaceuticals Revenue, 2017-2028

6.4.2 Germany Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4.3 France Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4.4 U.K. Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4.5 Italy Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4.6 Russia Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4.7 Nordic Countries Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.4.8 Benelux Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Non-oncology Biopharmaceuticals Revenue, 2017-2028

6.5.2 China Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.5.3 Japan Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.5.4 South Korea Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.5.5 Southeast Asia Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.5.6 India Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Non-oncology Biopharmaceuticals Revenue, 2017-2028

6.6.2 Brazil Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.6.3 Argentina Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Non-oncology Biopharmaceuticals Revenue, 2017-2028

6.7.2 Turkey Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.7.3 Israel Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.7.4 Saudi Arabia Non-oncology Biopharmaceuticals Market Size, 2017-2028

6.7.5 UAE Non-oncology Biopharmaceuticals Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche

7.1.1 Roche Corporate Summary

7.1.2 Roche Business Overview

7.1.3 Roche Non-oncology Biopharmaceuticals Major Product Offerings

7.1.4 Roche Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)

7.1.5 Roche Key News

7.2 Sanofi

- 7.2.1 Sanofi Corporate Summary
- 7.2.2 Sanofi Business Overview
- 7.2.3 Sanofi Non-oncology Biopharmaceuticals Major Product Offerings
- 7.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
- 7.2.5 Sanofi Key News
- 7.3 Johnson & Johnson
 - 7.3.1 Johnson & Johnson Corporate Summary
 - 7.3.2 Johnson & Johnson Business Overview
 - 7.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.3.5 Johnson & Johnson Key News
- 7.4 Pfizer
 - 7.4.1 Pfizer Corporate Summary
 - 7.4.2 Pfizer Business Overview
 - 7.4.3 Pfizer Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.4.5 Pfizer Key News
- 7.5 Novo Nordisk
 - 7.5.1 Novo Nordisk Corporate Summary
 - 7.5.2 Novo Nordisk Business Overview
 - 7.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.5.5 Novo Nordisk Key News
- 7.6 Novartis
 - 7.6.1 Novartis Corporate Summary
 - 7.6.2 Novartis Business Overview
 - 7.6.3 Novartis Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.6.4 Novartis Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.6.5 Novartis Key News
- 7.7 Merck
 - 7.7.1 Merck Corporate Summary
 - 7.7.2 Merck Business Overview
 - 7.7.3 Merck Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.7.4 Merck Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.7.5 Merck Key News
- 7.8 Teva

- 7.8.1 Teva Corporate Summary
- 7.8.2 Teva Business Overview
- 7.8.3 Teva Non-oncology Biopharmaceuticals Major Product Offerings
- 7.8.4 Teva Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
- 7.8.5 Teva Key News
- 7.9 Eli Lilly
 - 7.9.1 Eli Lilly Corporate Summary
 - 7.9.2 Eli Lilly Business Overview
 - 7.9.3 Eli Lilly Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.9.5 Eli Lilly Key News
- 7.10 Bristol-Myers Squibb
 - 7.10.1 Bristol-Myers Squibb Corporate Summary
 - 7.10.2 Bristol-Myers Squibb Business Overview
 - 7.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.10.5 Bristol-Myers Squibb Key News
- 7.11 GlaxoSmithKline
 - 7.11.1 GlaxoSmithKline Corporate Summary
 - 7.11.2 GlaxoSmithKline Business Overview
 - 7.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.11.5 GlaxoSmithKline Key News
- 7.12 UCB Pharma
 - 7.12.1 UCB Pharma Corporate Summary
 - 7.12.2 UCB Pharma Business Overview
 - 7.12.3 UCB Pharma Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.12.5 UCB Pharma Key News
- 7.13 Amgen
 - 7.13.1 Amgen Corporate Summary
 - 7.13.2 Amgen Business Overview
 - 7.13.3 Amgen Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.13.4 Amgen Non-oncology Biopharmaceuticals Revenue in Global Market

(2017-2022)

7.13.5 Amgen Key News

7.14 AbbVie

7.14.1 AbbVie Corporate Summary

7.14.2 AbbVie Business Overview

7.14.3 AbbVie Non-oncology Biopharmaceuticals Major Product Offerings

7.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue in Global Market

(2017-2022)

7.14.5 AbbVie Key News

7.15 Takeda

7.15.1 Takeda Corporate Summary

7.15.2 Takeda Business Overview

7.15.3 Takeda Non-oncology Biopharmaceuticals Major Product Offerings

7.15.4 Takeda Non-oncology Biopharmaceuticals Revenue in Global Market

(2017-2022)

7.15.5 Takeda Key News

7.16 AstraZeneca

7.16.1 AstraZeneca Corporate Summary

7.16.2 AstraZeneca Business Overview

7.16.3 AstraZeneca Non-oncology Biopharmaceuticals Major Product Offerings

7.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue in Global Market

(2017-2022)

7.16.5 AstraZeneca Key News

7.17 Mylan

7.17.1 Mylan Corporate Summary

7.17.2 Mylan Business Overview

7.17.3 Mylan Non-oncology Biopharmaceuticals Major Product Offerings

7.17.4 Mylan Non-oncology Biopharmaceuticals Revenue in Global Market

(2017-2022)

7.17.5 Mylan Key News

7.18 LEO Pharma

7.18.1 LEO Pharma Corporate Summary

7.18.2 LEO Pharma Business Overview

7.18.3 LEO Pharma Non-oncology Biopharmaceuticals Major Product Offerings

7.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue in Global Market

(2017-2022)

7.18.5 LEO Pharma Key News

7.19 Boehringer Ingelheim

7.19.1 Boehringer Ingelheim Corporate Summary

- 7.19.2 Boehringer Ingelheim Business Overview
- 7.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Major Product Offerings
- 7.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
- 7.19.5 Boehringer Ingelheim Key News
- 7.20 Alexion Pharmaceuticals
 - 7.20.1 Alexion Pharmaceuticals Corporate Summary
 - 7.20.2 Alexion Pharmaceuticals Business Overview
 - 7.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.20.5 Alexion Pharmaceuticals Key News
- 7.21 Elusys Therapeutics
 - 7.21.1 Elusys Therapeutics Corporate Summary
 - 7.21.2 Elusys Therapeutics Business Overview
 - 7.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.21.5 Elusys Therapeutics Key News
- 7.22 Swedish Orphan Biovitrum
 - 7.22.1 Swedish Orphan Biovitrum Corporate Summary
 - 7.22.2 Swedish Orphan Biovitrum Business Overview
 - 7.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.22.5 Swedish Orphan Biovitrum Key News
- 7.23 Biogen
 - 7.23.1 Biogen Corporate Summary
 - 7.23.2 Biogen Business Overview
 - 7.23.3 Biogen Non-oncology Biopharmaceuticals Major Product Offerings
 - 7.23.4 Biogen Non-oncology Biopharmaceuticals Revenue in Global Market (2017-2022)
 - 7.23.5 Biogen Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Non-oncology Biopharmaceuticals Market Opportunities & Trends in Global Market

Table 2. Non-oncology Biopharmaceuticals Market Drivers in Global Market

Table 3. Non-oncology Biopharmaceuticals Market Restraints in Global Market

Table 4. Key Players of Non-oncology Biopharmaceuticals in Global Market

Table 5. Top Non-oncology Biopharmaceuticals Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Non-oncology Biopharmaceuticals Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Non-oncology Biopharmaceuticals Revenue Share by Companies, 2017-2022

Table 8. Global Companies Non-oncology Biopharmaceuticals Product Type

Table 9. List of Global Tier 1 Non-oncology Biopharmaceuticals Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Non-oncology Biopharmaceuticals Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Non-oncology Biopharmaceuticals Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Non-oncology Biopharmaceuticals Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Non-oncology Biopharmaceuticals Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Non-oncology Biopharmaceuticals Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Non-oncology Biopharmaceuticals Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Non-oncology Biopharmaceuticals Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Non-oncology Biopharmaceuticals Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2023-2028

Table 30. Roche Corporate Summary

Table 31. Roche Non-oncology Biopharmaceuticals Product Offerings

Table 32. Roche Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 33. Sanofi Corporate Summary

Table 34. Sanofi Non-oncology Biopharmaceuticals Product Offerings

Table 35. Sanofi Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 36. Johnson & Johnson Corporate Summary

Table 37. Johnson & Johnson Non-oncology Biopharmaceuticals Product Offerings

Table 38. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 39. Pfizer Corporate Summary

Table 40. Pfizer Non-oncology Biopharmaceuticals Product Offerings

Table 41. Pfizer Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 42. Novo Nordisk Corporate Summary

Table 43. Novo Nordisk Non-oncology Biopharmaceuticals Product Offerings

Table 44. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 45. Novartis Corporate Summary

Table 46. Novartis Non-oncology Biopharmaceuticals Product Offerings

Table 47. Novartis Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 48. Merck Corporate Summary
Table 49. Merck Non-oncology Biopharmaceuticals Product Offerings
Table 50. Merck Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 51. Teva Corporate Summary
Table 52. Teva Non-oncology Biopharmaceuticals Product Offerings
Table 53. Teva Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 54. Eli Lilly Corporate Summary
Table 55. Eli Lilly Non-oncology Biopharmaceuticals Product Offerings
Table 56. Eli Lilly Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 57. Bristol-Myers Squibb Corporate Summary
Table 58. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Offerings
Table 59. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 60. GlaxoSmithKline Corporate Summary
Table 61. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Offerings
Table 62. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 63. UCB Pharma Corporate Summary
Table 64. UCB Pharma Non-oncology Biopharmaceuticals Product Offerings
Table 65. UCB Pharma Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 66. Amgen Corporate Summary
Table 67. Amgen Non-oncology Biopharmaceuticals Product Offerings
Table 68. Amgen Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 69. AbbVie Corporate Summary
Table 70. AbbVie Non-oncology Biopharmaceuticals Product Offerings
Table 71. AbbVie Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 72. Takeda Corporate Summary
Table 73. Takeda Non-oncology Biopharmaceuticals Product Offerings
Table 74. Takeda Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 75. AstraZeneca Corporate Summary
Table 76. AstraZeneca Non-oncology Biopharmaceuticals Product Offerings
Table 77. AstraZeneca Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 78. Mylan Corporate Summary
Table 79. Mylan Non-oncology Biopharmaceuticals Product Offerings
Table 80. Mylan Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)
Table 81. LEO Pharma Corporate Summary
Table 82. LEO Pharma Non-oncology Biopharmaceuticals Product Offerings

Table 83. LEO Pharma Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 84. Boehringer Ingelheim Corporate Summary

Table 85. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Offerings

Table 86. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 87. Alexion Pharmaceuticals Corporate Summary

Table 88. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Offerings

Table 89. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 90. Elusys Therapeutics Corporate Summary

Table 91. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Offerings

Table 92. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 93. Swedish Orphan Biovitrum Corporate Summary

Table 94. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Offerings

Table 95. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

Table 96. Biogen Corporate Summary

Table 97. Biogen Non-oncology Biopharmaceuticals Product Offerings

Table 98. Biogen Non-oncology Biopharmaceuticals Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Non-oncology Biopharmaceuticals Segment by Type in 2021

Figure 2. Non-oncology Biopharmaceuticals Segment by Application in 2021

Figure 3. Global Non-oncology Biopharmaceuticals Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Non-oncology Biopharmaceuticals Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Non-oncology Biopharmaceuticals Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Non-oncology Biopharmaceuticals Revenue in 2021

Figure 8. By Type - Global Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 9. By Application - Global Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 10. By Region - Global Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 11. By Country - North America Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 12. US Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 16. Germany Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 17. France Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 24. China Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 28. India Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 30. Brazil Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Non-oncology Biopharmaceuticals Revenue Market Share, 2017-2028

Figure 33. Turkey Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Non-oncology Biopharmaceuticals Revenue, (US\$, Mn), 2017-2028

Figure 37. Roche Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Sanofi Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pfizer Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Novo Nordisk Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Novartis Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Merck Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Teva Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Eli Lilly Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. UCB Pharma Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Amgen Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. AbbVie Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Takeda Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. AstraZeneca Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Mylan Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. LEO Pharma Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 55. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 57. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 58. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 59. Biogen Non-oncology Biopharmaceuticals Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Non-oncology Biopharmaceuticals Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/N0FB8405C4DCEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0FB8405C4DCEN.html>